Hot Small Cap Stocks For 2015

Hot Small Cap Stocks For 2015: Achillion Pharmaceuticals Inc.(ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Advisors' Opinion:

• [By Ben Levisohn]

  Stocks finished mix today, though it’s probably more fair to say they hardly moved at all.Intel(INTC), Facebook (FB) andAchillion Pharmaceuticals (ACHN) gained, whileCR Bard(BCR) and eHealth (EHTH) fell.

• [By John Udovich]

  While Intercept Pharmaceuticals Inc (NASDAQ: ICPT) surged earlier this year and Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) has surged this week after Merck & Co. Inc (NYSE: MRK) agreed to purchase hepatitis stockIdenix Pharmaceuticals Inc (NASDAQ: IDIX) at a 239% premium, it seems the herd has realized that small cap Conatus Pharmaceuticals Inc (NASDAQ: CNAT) is also a liver disease stock as shares suddenly surged 56.69% on no apparent company news. But just what isConatus Pharmaceuticals and is it worth taking a chance on?

!
• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Monday’s session are Achillion Pharmaceuticals Inc.(ACHN), Active Network Inc.(ACTV) and Harvest Natural Resources Inc.(HNR)

• [By David Williamson]

  In this video, David Williamson describes how Achillion Pharmaceuticals (NASDAQ: ACHN  ) may challenge Gilead's (NASDAQ: GILD  ) dominance in the Hepatitis C drug market. Achillion is concluding phase 2 clinical trials of its oral interferon medication, and so far, things are looking good. If successful in phase 3 trials, Achillion could directly challenge Gilead's interferon medication. For investors, the success of Achillion's drug is attractive, but the potential for Achillion to be a takeover target is even more enticing. The company has a market cap of around $575 million and could easily be bought out by the likes of Bristol-Myers Squibb.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/hot-small-cap-stocks-for-2015-2.html